Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer

Conference Correspondent  - ESMO Highlights

Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that is approved in the United States for patients with advanced breast cancer and advanced ovarian cancer. For patients receiving treatment for advanced cancer, fatigue and neuropathy―the latter in particular for those receiving platinum and/or taxanes―are among the most commonly reported adverse events.1 In this study, Ruiz-Schutz and colleagues performed a systematic literature review and meta-analysis of randomized controlled trials to characterize the risk for fatigue and neuropathy associated with the use of olaparib.

Nine studies representing 2074 patients with advanced ovarian, gastric, prostate, lung, or breast cancer were included in this analysis, with 908 (43.7%) patients receiving placebo/control treatments and 1166 (56.2%) receiving olaparib alone or in association with other active cancer treatments. Olaparib use was associated with increases in both all-grade fatigue (relative risk [RR], 1.24; 95% confidence interval [CI], 1.10-1.39) and high fatigue (hazard ratio [HR], 1.55; 95% CI, 1.14-2.09), as well as increases in high-grade fatigue (HR, 1.71; 95% CI, 1.06-2.77).

These results suggest that olaparib treatment is associated with an increased risk of fatigue. Given that fatigue is a very common treatment-related adverse event that can impair patients’ quality of life, it is important to identify it early and manage it accordingly to optimize overall treatment.

Reference

  1. Ruiz-Schutz, et al. ESMO 2018. Abstract 982P.
Related Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO Highlights
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Safety and Efficacy of XMT-1536 in Ovarian Cancer: Subgroup Analysis from a Phase 1 Expansion Study
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Atezolizumab in Patients with Newly Diagnosed Stage III or Stage IV Ovarian Cancer
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Mirvetuximab Soravtansine in Combination with Carboplatin and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Patient-Reported Outcomes in Patients Receiving Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: The NINJA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Individualized Starting Dose of Niraparib to Treat Platinum-Sensitive Recurrent Ovarian Cancer: The NORA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.